Reduced Expression of VEGF-A in Human Retinal Pigment Epithelial Cells and Human Muller Cells Following CRISPR-Cas9 Ribonucleoprotein-Mediated Gene Disruption

Ameri, Hossein; Murat, Christopher; Arbabi, Amirmohsen; Jiang, Wei; Janga, Srikanth Reddy; Qin, Peter Z.

doi:10.1167/tvst.9.8.23

Cited by 5 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By targeting and disrupting the VEGF gene using CRISPR-Cas9, researchers can potentially hinder the production of VEGF and, consequently, inhibit tumor angiogenesis. This could lead to reduced tumor growth and increased sensitivity to other cancer treatments [130]. While CRISPR-Cas9 is highly specific, there is a possibility of off-target effects where unintended gene edits occur.…”

Section: Reduced Cell Proliferation and Tumor Growth In Micementioning

confidence: 99%

“…CRISPR-Cas9-based VEGF gene editing, on its own, may not be sufficient for complete cancer treatment [129]. While it can impede tumor angiogenesis, a comprehensive cancer treatment strategy usually involves combining CRISPR-Cas9 with other therapies like chemotherapy, radiation, or immunotherapy [130]. Combining treatments can lead to a synergistic effect, targeting cancer cells through multiple pathways and increasing the overall therapeutic efficacy [129].…”

Section: Reduced Cell Proliferation and Tumor Growth In Micementioning

confidence: 99%

“…CRISPR-Cas9 offers a precise and efficient method to edit the BCL-2 gene and potentially restore normal cell death mechanisms [133]. CRISPR-Cas9 utilizes guide RNAs designed to match specific sequences within the BCL-2 gene [130]. When the guide RNA finds a complementary match, it guides the Cas9 enzyme to that location, initiating a double-stranded DNA break at the target site [134].…”

Section: Reduced Cell Proliferation and Tumor Growth In Micementioning

confidence: 99%

See 2 more Smart Citations

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

Chehelgerdi,

Khorramian-Ghahfarokhi

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

The CRISPR system is a revolutionary genome editing tool that has the potential to revolutionize the field of cancer research and therapy. The ability to precisely target and edit specific genetic mutations that drive the growth and spread of tumors has opened up new possibilities for the development of more effective and personalized cancer treatments. In this review, we will discuss the different CRISPR-based strategies that have been proposed for cancer therapy, including inactivating genes that drive tumor growth, enhancing the immune response to cancer cells, repairing genetic mutations that cause cancer, and delivering cancer-killing molecules directly to tumor cells. We will also summarize the current state of preclinical studies and clinical trials of CRISPR-based cancer therapy, highlighting the most promising results and the challenges that still need to be overcome. Safety and delivery are also important challenges for CRISPR-based cancer therapy to become a viable clinical option. We will discuss the challenges and limitations that need to be overcome, such as off-target effects, safety, and delivery to the tumor site. Finally, we will provide an overview of the current challenges and opportunities in the field of CRISPR-based cancer therapy and discuss future directions for research and development. The CRISPR system has the potential to change the landscape of cancer research, and this review aims to provide an overview of the current state of the field and the challenges that need to be overcome to realize this potential.

show abstract

Section: Reduced Cell Proliferation and Tumor Growth In Micementioning

confidence: 99%

Section: Reduced Cell Proliferation and Tumor Growth In Micementioning

confidence: 99%

Section: Reduced Cell Proliferation and Tumor Growth In Micementioning

confidence: 99%

See 1 more Smart Citation

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

Chehelgerdi,

Khorramian-Ghahfarokhi

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…CRISPR/Cas9 technology offers promising therapeutic avenues for addressing such diseases. Ameri and colleagues [157] utilized liposomes as carriers to deliver CRISPR-Cas9 RNP complexes for targeting Muller and RPE cells, which are the primary producers of VEGF-A protein. The objective was to disrupt the VEGF-A gene, leading to a significant decrease in VEGF-A protein levels.…”

Section: Biomedical Applications Of Crispr/cas9 Systemmentioning

confidence: 99%

CRISPR/Cas9 systems: Delivery technologies and biomedical applications

Du,

Liu,

et al. 2023

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Harnessing Gene Editing Technology for Tumor Microenvironment Modulation: An Emerging Anticancer Strategy

Feng,

Zhang,

Wang

et al. 2024

Chemistry A European J

View full text Add to dashboard Cite

Cancer is a multifaceted disease influenced by both intrinsic cellular traits and extrinsic factors, with the tumor microenvironment (TME) being crucial for cancer progression. To satisfy their high proliferation and aggressiveness, cancer cells always plunder large amounts of nutrients and release various signals to their surroundings, forming a dynamic TME with special metabolic, immune, microbial and physical characteristics. Due to the neglect of interactions between tumor cells and the TME, traditional cancer therapies often struggle with challenges such as drug resistance, low efficacy, and recurrence. Importantly, the development of gene editing technologies, particularly the CRISPR‐Cas system, offers promising new strategies for cancer treatment. Combined with nanomaterial strategies, CRISPR‐Cas technology exhibits precision, affordability, and user‐friendliness with reduced side effects, which holds great promise for profoundly altering the TME at the genetic level, potentially leading to lasting anticancer outcomes. This review will delve into how CRISPR‐Cas can be leveraged to manipulate the TME, examining its potential as a transformative anticancer therapy.

show abstract

Reduced Expression of VEGF-A in Human Retinal Pigment Epithelial Cells and Human Muller Cells Following CRISPR-Cas9 Ribonucleoprotein-Mediated Gene Disruption

Abstract: Hamm-Alvarez SF. Reduced expression of VEGF-A in human retinal pigment epithelial cells and human muller cells following CRISPR-Cas9 ribonucleoprotein-mediated gene disruption.

Cited by 5 publications

References 30 publications

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

CRISPR/Cas9 systems: Delivery technologies and biomedical applications

Harnessing Gene Editing Technology for Tumor Microenvironment Modulation: An Emerging Anticancer Strategy

Contact Info

Product

Resources

About